Article

Evaluation of Depression as a Risk Factor for Treatment Failure in Chronic Hepatitis C

Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark.
Hepatology (Impact Factor: 11.06). 08/2010; 52(2):430-5. DOI: 10.1002/hep.23699
Source: PubMed

ABSTRACT

The Major Depression Inventory (MDI) was used to estimate the value of routine medical interviews in diagnosing major depression among patients receiving peginterferon alfa-2a and ribavirin therapy for chronic hepatitis C virus (HCV) infection (n = 325). According to criteria from the MDI and Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 19 patients (6%) had major depression at baseline. An additional 114 (37%) developed depression while on HCV combination therapy, with baseline MDI score and female sex independently predicting the emergence of major depression during treatment in a multivariate analysis. Only 36 (32%) of the 114 patients developing major depression according to MDI/DSM-IV criteria were correctly diagnosed during routine medical interviews. The emergence of major depression frequently led to premature discontinuation of peginterferon/ribavirin therapy, and an on-treatment MDI score increment exceeding 30 points (i.e., a validated marker of idiopathic DSM-IV major depression) was correlated with impaired outcome of HCV therapy (P = 0.02). This difference was even more pronounced among patients with an on-treatment increase in MDI score greater than 35 points (P = 0.003). Conclusion: We conclude that (1) depressive symptoms among patients undergoing HCV therapy are commonly overlooked by routine clinical interviews, (2) the emergence of depression compromises the outcome of HCV therapy, and (3) the MDI scale may be useful in identifying patients at risk for treatment-induced depression.

Download full-text

Full-text

Available from: Martin Lagging
    • "hepatitis C) and tumors. However, despite therapeutic efficacy in these illnesses, it has been observed that IFN-α2 therapy is associated with neuroinflammation, neurodegeneration and with the development of psychiatric side-effects (Alboni et al. 2013; Hofer and Campbell 2013; Leutscher et al. 2010; Paul et al. 2007; Spennati and Pariante 2013; Taylor et al. 2014). In order to develop therapeutic strategies aimed at counteracting IFN-α2-induced effects on the nervous system, without interfering with the efficacy of the antiviral treatment, molecular effects on brain cells triggered by exposure to the cytokines (including neurons) have to be fully characterized. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Interferon (IFN)-α2 is an extensively therapeutically used pro-inflammatory cytokine. Though its efficacy in controlling viral replication and tumor cells proliferation, administration of IFN-α2 is often associated with the development of central side effects. Magnetic resonance spectroscopy studies have demonstrated that IFN-α2 administration affects brain metabolism, however the exact nature of this effect is not completely known. We hypothesized that IFN-α2 can affect metabolic activity of human neuron-like SH-SY5Y cells which possess many characteristics of neurons and represent one of the most used models for studying mechanisms involved in neurotoxicity or neuroprotection. To test our hypothesis we have characterized the metabolic signature of live SH-SY5Y, and their conditioned media, after 24 and 72 h of exposure to vehicle or IFN-α2 (100 ng/ml) by using High Resolution-Magic Angle Spinning (HR-MAS) Nuclear Magnetic Resonance (NMR) spectroscopy. Our results revealed that 1) the use of HR-MAS NMR is ideally suitable for the characterization of the metabolic profile of live cells and their conditioned media without extraction procedures; and 2) a 72 h exposure to IFN-α2 increases the level of metabolites involved in maintaining energetic (including creatine and lactate) and osmotic (such as myo-inositol, scyllo-inositol, taurine and glycerophosphorylcholine) balances in neuron-like cells and of metabolic waste products (namely lactate, ethanol and acetate), glycine and glutamine in their growth media. These results may contribute to gain more knowledge about the IFN-α2 induced effect on the brain and support the interpretation of magnetic resonance spectroscopy studies performed in humans.
    No preview · Article · Nov 2015 · Journal of Neuroimmune Pharmacology
  • Source
    • "Depression Research and Treatment criteria, screening tools, and study population [3] [4] [5] [6]. The psychiatric evaluation of patients with HCV was commonly performed by clinicians with limited psychiatric training. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective and Methods. Although the interaction between fatigue and depression in patients with chronic hepatitis C infection (HCV) has been recognized, the biological correlates of this observation have yet to be reported. We addressed this issue by examining serotonin transporter- (SERT-) driven [(14)C]-serotonin uptake rate (SUR) and serotonin content in platelets of 65 untreated HCV patients and 65 healthy control subjects (HCS). All patients completed report questionnaires for fatigue, depression, and general psychopathology. Structured interviews were conducted by a board-certified psychiatrist. Results. Whereas 36 of the patients experienced fatigue of moderate-to-severe intensity, only 16 reported symptoms of depression (BDI score > 10). Mean SUR in patients with depressive symptoms was significantly higher relative to the HCS, corresponding to a large Cohen's effect size of d = 1.45 (95% CI = 0.66-1.83). Patients who rated their fatigue to have a marked impact on mood and activity displayed a moderate relationship between the BDI score and SUR (n = 18, r = 0.563, P = 0.015), which becomes stronger after controlling for age, gender, and thrombocytopenia (r part = 0.710, P = 0.003). In the univariate analysis, high fatigue interference score, thrombocytopenia, and high SUR were all significant predictors of depression. Conclusions. High SERT activity could be implicated in the expression of depressive symptoms especially in a subgroup of HCV patients who are feeling fatigue as markedly distressing.
    Full-text · Article · Mar 2014 · Depression research and treatment
  • Source
    • "Furthermore, the presence of psychological symptoms can be exacerbated by the neuropsychiatric side-effects of anti-viral treatment with interferon (Castera et al., 2006; Leutscher et al., 2010; Martín-Santos et al., 2008). This can necessitate the need for dose reduction or treatment cessation , subsequently leading to decreased treatment success rates (Leutscher et al., 2010; Raison et al., 2005). As a consequence , many patients with psychiatric co-morbidity are delayed or excluded from treatment (Chainuvati et al., 2006; Evon et al., 2007, 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the prevalence of psychiatric co-morbidity in chronic hepatitis C (CHC), treatment is under-researched. Patient preferences are likely to affect treatment uptake, adherence, and success. Thus, the acceptability of psychological supports was explored. A postal survey of Australian CHC outpatients of the Royal Adelaide Hospital and online survey of Australians living with CHC was conducted, assessing demographic and disease-related variables, psychosocial characteristics, past experience with psychological support, and psychological support acceptability. The final sample of 156 patients (58 % male) had significantly worse depression, anxiety, stress, and social support than norms. The most acceptable support type was individual psychotherapy (83 %), followed by bibliotherapy (61 %), pharmacotherapy (56 %), online therapy (45 %), and group psychotherapy (37 %). The most prominent predictor of support acceptability was satisfaction with past use. While individual psychotherapy acceptability was encouragingly high, potentially less costly modalities including group psychotherapy or online therapy may be hampered by low acceptability, the reasons for which need to be further explored.
    Full-text · Article · Jun 2013 · Journal of Clinical Psychology in Medical Settings
Show more